Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
Titel:
Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
Auteur:
O’Shaughnessy, J.A. Blum, J. Moiseyenko, V. Jones, S.E. Miles, D. Bell, D. Rosso, R. Mauriac, L. Osterwalder, B. Burger, H.-U. Laws, S.